Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization. Issue 3 (3rd February 2021)

• Record Type: Journal Article
• Authors: De Stefano, Nicola; Giorgio, Antonio; Gentile, Giordano; Stromillo, Maria Laura; Cortese, Rosa; Gasperini, Claudio; Visconti, Andrea; Sormani, Maria Pia; Battaglini, Marco
• Is Part Of: Annals of clinical and translational neurology. Volume 8:Issue 3(2021)
• Page Start: 623
• Page End: 630
• Publication Date: 2021-02-03
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1002/acn3.51302
• Languages: English
• ISSNs: 2328-9503

Abstract

Abstract: Objective: To assess the dynamics of "pseudo‐atrophy, " the accelerated brain volume loss observed after initiation of anti‐inflammatory therapies, in patients with multiple sclerosis (MS). Methods: Monthly magnetic resonance imaging (MRI) data of patients from the IMPROVE clinical study (NCT00441103) comparing relapsing‐remitting MS patients treated with interferon beta‐1a (IFNβ‐1a) for 40 weeks versus those receiving placebo (16 weeks) and then IFNβ‐1a (24 weeks) were used to assess percentage of gray (PGMVC) and white matter (PWMVC) volume changes. Comparisons of PGMVC and PWMVC slopes were performed with a mixed effect linear model. In the IFNβ‐1a‐treated arm, a quadratic term was included in the model to evaluate the plateauing effect over 40 weeks. Results: Up to week 16, PGMVC was −0.14% per month in the placebo and −0.27% per month in treated patients ( P < 0.001). Over the same period, the decrease in PWMVC was −0.067% per month in the placebo and −0.116% per month in treated patients ( P = 0.27). Similar changes were found in the group originally randomized to placebo when starting IFNβ‐1a treatment (week 16–40, reliability analysis). In the originally treated group, over 40 weeks, the decrease in PGMVC showed a significant ( P < 0.001) quadratic component, indicating a plateauing at week 20. Interpretation: Findings reported here add new insights into the complex mechanisms of pseudo‐atrophy and its relation to the compartmentalized inflammation occurring in the GM of MS patients. Ongoing and forthcoming clinical trials including MRI‐derived GM volume loss as an outcome measure need to account for potentially significant GM volume changes as part of the initial treatment effect.